GO
Loading...

Rigel Pharmaceuticals Inc

More

  • UPDATE 2-Rigel eye drug fails mid-stage study, shares fall Wednesday, 13 Aug 2014 | 10:48 AM ET

    Aug 13- Rigel Pharmaceuticals Inc said it would stop testing its drug for some patients with dry eye disease after the treatment failed a mid-stage study. British drugmaker AstraZeneca Plc scrapped its licensing deal for Rigel's rheumatoid arthritis treatment in June 2013.

  • Aug 13- Rigel Pharmaceuticals Inc said its experimental drug failed to meet the main goal in a mid-stage study in patients with dry eye disease, sending its shares down 10.7 percent in premarket trading. British drugmaker AstraZeneca stopped developing Rigel's rheumatoid arthritis treatment in June 2013.

  • Rigel experimental eye drug fails mid-stage study Wednesday, 13 Aug 2014 | 7:44 AM ET

    Aug 13- Rigel Pharmaceuticals Inc said its experimental drug failed to meet the main goal in a mid-stage study in patients with dry eye disease. The study was testing the drug, R348, against a placebo in the trial.

  • Early Movers: AAPL, UNH, MSFT, TM & More Wednesday, 5 Jun 2013 | 7:40 AM ET

    Some of the names on the move ahead of the open.

  • Early Movers: AIG, DELL, DG, FDX, BWLD & More Tuesday, 4 Jun 2013 | 7:32 AM ET

    Some of the names on the move ahead of the open.

  • 5 Stocks Poised for Breakouts: Technical Analysis Monday, 15 Apr 2013 | 4:00 PM ET
    The 3D Systems modeling printer.

    The pros know that once a stock starts to break past resistance levels, it can easily trend significantly higher. TheStreet.com looks at five stocks.

  • MARKET PULSE-Sarepta, HP, Leap, Ocwen, Netflix, Adtran Wednesday, 3 Oct 2012 | 1:54 PM ET

    U.S. stocks advanced on Wednesday after stronger-than-expected employment and service-sector data in the United States. But a gloomier outlook in China and Europe weighed on commodity prices and hit energy and materials shares. **SAREPTA THERAPEUTICS INC, $41.60, up 177 pct.

  • U.S. stocks rose on Wednesday after stronger-than-expected employment and service-sector data in the United States, but a gloomier outlook in China and Europe weighed on commodity prices and hit energy and materials shares. **SAREPTA THERAPEUTICS INC, $40.65, up 171 pct. **HEWLETT-PACKARD CO, $15.67, down 8.4 pct.

  • **SAREPTA THERAPEUTICS INC, $40.19, up 168 pct. **BIOLASE INC, $2.11, up 27 pct. The company said health regulators in Europe and the United States approved its laser device for use in soft tissue surgery, teeth whitening, and pain therapy.

  • Shares of Rigel Pharma fall on stock offering Wednesday, 3 Oct 2012 | 11:15 AM ET

    SOUTH SAN FRANCISCO, Calif.-- Drug developer Rigel Pharmaceuticals Inc. said it priced its public offering of 13.7 million shares of its common stock at $9.50 per share. The South San Francisco, Calif.- based company said it expects the offering's gross proceeds to total about $130 million, before deducting underwriting discounts, commissions, and other expenses.

  • The Nasdaq Composite Index rose 0.37 percent. **SAREPTA THERAPEUTICS INC, $30.30, up 102 pct. **INTERMUNE INC, $9.74, up 10 pct.

  • **SAREPTA THERAPEUTICS INC, Tuesday close $14.99, up 135 pct premarket. **HEWLETT-PACKARD CO, Tuesday close $17.13, up 0.4 pct premarket. **GOOGLE INC, Tuesday close $756.99, up 0.13 pct premarket.

  • Oct 3- Rigel Pharmaceuticals Inc:. *Announces pricing of public offering of common stock. *Says public offering of 13.7 million common shares priced at $9.50 per share.

  • **SAREPTA THERAPEUTICS INC, Tuesday close $14.99, up 135 pct premarket. **HEWLETT-PACKARD CO, Tuesday close $17.13, up 0.4 pct premarket. **GOOGLE INC, Tuesday close $756.99, up 0.13 pct premarket.

  • Oct 2- Rigel Pharmaceuticals Inc:. *Announces proposed public offering of common stock. *Proceeds to be used to fund research and development activities and for.

  • Cramer's Calls on 5 Stocks Thursday, 1 Dec 2011 | 8:03 PM ET

    The "Mad Money" host opens his mailbag and answers viewer's questions.

  • Rivals Gain on Pfizer Drug Trial News Thursday, 21 Apr 2011 | 5:42 PM ET

    I noted on the air this afternoon that Pfizer, which was trading at about $20.20, dropped in a few minutes to about $19.50 on heavy volume.

  • Options Action Points to Hershey, Rigel Pharma Thursday, 7 Aug 2008 | 10:49 AM ET

    Options trading points toward developments at Hershey -- similar to what swirled around Anheuser-Busch -- according to Interactive Brokers' Rebecca Darst.

  • US Stocks Hit by Inflation Worries Friday, 14 Dec 2007 | 4:40 PM ET

    Inflation took the spotlight as the newest fear to haunt investors, sending stocks down to end a volatile week that featured more credit worries and pervasive unease over the Fed's role in the market.

  • Stocks Close Mixed As Dow Rebounds Thursday, 13 Dec 2007 | 3:59 PM ET

    Stocks closed mixed as worries about a weakening economy and credit crunch continued to rattle the markets.